register

News - Pharmaceuticals

Noxopharm announces new CEO ahead of growth phase

Health Industry Hub | January 14, 2022 |

Pharma News: Australian clinical-stage drug development company Noxopharm announced an executive transition which places the Company in a great position to move into the next phase of its growth and expansion.

Dr Gisela Mautner will be appointed as the Chief Executive Officer from 1 February 2022, with Dr Graham Kelly remaining on the Board as a Non-Executive Director and shifting from an executive to a consultant role. Dr Mautner, currently the Company’s Chief Medical Officer, also will serve on the Board as Executive Managing Director.

Noxopharm CEO, Dr Kelly, said “The Company is in the process of transiting from an early-stage biotech company into a serious biopharma company looking to make its mark on the world stage. I made the decision several months ago that 2022 was the time for a generational change and time to hand over to someone with large pharma industry experience who could oversee the Company position itself as a valuable partnering opportunity. Having worked alongside Gisela for several years now, I have full confidence in her ability to achieve that objective. I believe she will make an outstanding CEO.

Dr Mautner, who is also the past President of the Australian Pharmaceutical medical and scientific Professionals Association (APPA), said “Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the Company through its next stages. I look forward to working with the Board and the talented team at Noxopharm to deliver success and value for our many stakeholders. A new Department Head is being appointed to oversee the delivery of our Clinical Development Program.”

You may also like: Cancer patients hit hard by cuts to telehealth rebates

Noxopharm Non-Executive Chairman, Mr Fred Bart, commented “Graham has, with the full support of the Board, chosen to transition from the CEO/MD role and has accepted the Board’s invitation to continue as a non-executive director and as a consultant to support Gisela as required. The Board would like to thank Graham for his unrelenting dedication and commitment to Noxopharm and welcomes his ongoing contribution. The Board regards Gisela as an outstanding successor and is confident in her ability to create and advance significant shareholder value in the years ahead.”

Dr Kelly added “As the Company’s largest shareholder, ongoing Board member and Inventor of much of the Company’s intellectual property, I intend to remain actively involved in the Company’s future.”


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.